Flublok proves more effective than traditional influenza vaccine
According to the clinical study, the new Flublok surpassed the traditional vaccine in both preventing the flu and in lasting the entire season.
In the study, researchers compared the new Flublok Quadrivalent to an inactivated, traditional, egg-based quadrivalent vaccine. The data suggests that Flublok performed better because a notably lower number of people reported flu illnesses after receiving the new vaccine.
The clinical trial involved approximately 9,000 subjects, all of them age 50 or more. Half of these volunteers received the Flublock Quadrivalent influenza vaccine, and the remaining half were administered the quadrivalent inactivated influenza vaccine that is egg-based. Approximately 31 percent more people received adequate protection from Flublok compared to the traditional vaccine.
"This study points out the advantages of using modern technology to overcome problems with traditional influenza vaccine manufacturing," Protein Sciences President and CEO Manon Cox said. "Ten years ago we had the first evidence in clinical trial PSC01 that more antigen was beneficial even for healthy adults. Today with support from the Biomedical Advanced Research and Development Authority (BARDA) we were able to show statistically significant better performance than traditional egg-produced vaccines."